Biogen Idec Inc. - Product Pipeline Review - 2014

  • ID: 2826065
  • Company Profile
  • 102 pages
  • Global Markets Direct
  • Biogen Inc.
1 of 4
Biogen Idec Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Biogen Idec Inc. - Product Pipeline Review - 2014’, provides an overview of the Biogen Idec Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biogen Idec Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biogen Idec Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biogen Idec Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Biogen Idec Inc.’s pipeline products

Reasons to buy

- Evaluate Biogen Idec Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biogen Idec Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biogen Idec Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biogen Idec Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biogen Idec Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biogen Idec Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Table of Contents
Table of Contents
List of Tables
List of Figures
Biogen Idec Inc. Snapshot
Biogen Idec Inc. Overview
Key Information
Key Facts
Biogen Idec Inc. - Research and Development Overview
Key Therapeutic Areas
Biogen Idec Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Biogen Idec Inc. - Pipeline Products Glance
Biogen Idec Inc. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Biogen Idec Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Biogen Idec Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Biogen Idec Inc. - Drug Profiles
coagulation factor IX-Fc (recombinant)
Product Description
Mechanism of Action
R&D Progress
coagulation factor VIII-Fc (recombinant)
Product Description
Mechanism of Action
R&D Progress
dimethyl fumarate
Product Description
Mechanism of Action
R&D Progress
natalizumab
Product Description
Mechanism of Action
R&D Progress
peginterferon beta-1a
Product Description
Mechanism of Action
R&D Progress
BG-00010
Product Description
Mechanism of Action
R&D Progress
BIIB-023
Product Description
Mechanism of Action
R&D Progress
BIIB-033
Product Description
Mechanism of Action
R&D Progress
rituximab
Product Description
Mechanism of Action
R&D Progress
STX-100
Product Description
Mechanism of Action
R&D Progress
aducanumab
Product Description
Mechanism of Action
R&D Progress
BG-00001
Product Description
Mechanism of Action
R&D Progress
BIIB-059
Product Description
Mechanism of Action
R&D Progress
BIIB-061
Product Description
Mechanism of Action
R&D Progress
5D-10
Product Description
Mechanism of Action
R&D Progress
Antibodies to Inhibit Alpha Synuclein for Neurodegenerative Diseases
Product Description
Mechanism of Action
R&D Progress
BIIB-034
Product Description
Mechanism of Action
R&D Progress
BIIB-053
Product Description
Mechanism of Action
R&D Progress
BIIB-054
Product Description
Mechanism of Action
R&D Progress
Drug to Modulate Gamma Secretase for Alzheimer Disease
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis
Product Description
Mechanism of Action
R&D Progress
NI-105
Product Description
Mechanism of Action
R&D Progress
Recombinant Interleukin-34
Product Description
Mechanism of Action
R&D Progress
Recombinant Macrophage Colony Stimulating Factor
Product Description
Mechanism of Action
R&D Progress
TDP-43 Program
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Parkinsons Disease
Product Description
Mechanism of Action
R&D Progress
Biogen Idec Inc. - Pipeline Analysis
Biogen Idec Inc. - Pipeline Products by Target
Biogen Idec Inc. - Pipeline Products by Route of Administration
Biogen Idec Inc. - Pipeline Products by Molecule Type
Biogen Idec Inc. - Pipeline Products by Mechanism of Action
Biogen Idec Inc. - Recent Pipeline Updates
Biogen Idec Inc. - Dormant Projects
Biogen Idec Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
baminercept alfa
clenoliximab
CNF-1010
dexpramipexole dihydrochloride
naxifylline
vipadenant
Biogen Idec Inc. - Company Statement
Biogen Idec Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Biogen Idec Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Biogen Idec Inc., Key Information
Biogen Idec Inc., Key Facts
Biogen Idec Inc. - Pipeline by Indication, 2014
Biogen Idec Inc. - Pipeline by Stage of Development, 2014
Biogen Idec Inc. - Monotherapy Products in Pipeline, 2014
Biogen Idec Inc. - Partnered Products in Pipeline, 2014
Biogen Idec Inc. - Partnered Products/ Combination Treatment Modalities, 2014
Biogen Idec Inc. - Out-Licensed Products in Pipeline, 2014
Biogen Idec Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
Biogen Idec Inc. - Pre-Registration, 2014
Biogen Idec Inc. - Phase III, 2014
Biogen Idec Inc. - Phase II, 2014
Biogen Idec Inc. - Phase I, 2014
Biogen Idec Inc. - Preclinical, 2014
Biogen Idec Inc. - Discovery, 2014
Biogen Idec Inc. - Pipeline by Target, 2014
Biogen Idec Inc. - Pipeline by Route of Administration, 2014
Biogen Idec Inc. - Pipeline by Molecule Type, 2014
Biogen Idec Inc. - Pipeline Products by Mechanism of Action, 2014
Biogen Idec Inc. - Recent Pipeline Updates, 2014
Biogen Idec Inc. - Dormant Developmental Projects,2014
Biogen Idec Inc. - Discontinued Pipeline Products, 2014
Biogen Idec Inc., Other Locations
Biogen Idec Inc., Subsidiaries
Biogen Idec Inc., Key Manufacturing Facilities

List of Figures
Biogen Idec Inc. - Pipeline by Top 10 Indication, 2014
Biogen Idec Inc. - Pipeline by Stage of Development, 2014
Biogen Idec Inc. - Monotherapy Products in Pipeline, 2014
Biogen Idec Inc. - Partnered Products in Pipeline, 2014
Biogen Idec Inc. - Out-Licensed Products in Pipeline, 2014
Biogen Idec Inc. - Pipeline by Top 10 Target, 2014
Biogen Idec Inc. - Pipeline by Top 10 Route of Administration, 2014
Biogen Idec Inc. - Pipeline by Top 10 Molecule Type, 2014
Biogen Idec Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 63
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll